Skip to main content

Czirr James C's Form 4 filing

Galectin Therapeutics Inc (GALT) · filed Dec 4, 2025

Accession no.
0001493152-25-026204
Filed
Dec 4, 2025, 4:57 PM ET
Trade date
Dec 2-3, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market sales total $851.7K. It was filed 2 days after the trade.

This filing was later replaced by the amendment 0001493152-25-026587 (Dec 8, 2025). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Czirr James CCIK 000126064110% Owner
10X Fund, L.P.CIK 000145335610% Owner
10X Capital Management, LLCCIK 000145724710% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 2, 2025Common StockSSaleDisposed−30,000$5.47F2−$164,1005,802,207Direct
Dec 3, 2025Common StockSSaleDisposed−120,000$5.73F3−$687,6005,682,207Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The shares were sold in multiple transactions at prices ranging from $5.40 to $5.50. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

F3

The shares were sold in multiple transactions at prices ranging from $5.68 to $5.85. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)